HIV-associated kidney disease in the context of an aging population

Sexual Health

Volumn 8, Issue 4, 2011, Pages 485-492

  Naftalin, Claire ^a   Nathan, Bavithra ^a   Hamzah, Lisa ^a,b   Post, Frank A ^a,b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

acute renal failure; AIDS; chronic kidney disease; HIV associated nephropathy; proteinuria; renal function

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDINAVIR; LOPINAVIR; RITONAVIR; TENOFOVIR;

ACUTE KIDNEY FAILURE; AGING; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; DEVELOPED COUNTRY; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; LIFE EXPECTANCY; PROTEINURIA; RISK FACTOR; SCREENING; TREATMENT INDICATION;

ACUTE KIDNEY INJURY; AGED; AGING; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMORBIDITY; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; LIFE EXPECTANCY; RISK FACTORS;

EID: 81055123984     PISSN: 14485028     EISSN: 14498987     Source Type: Journal    
DOI: 10.1071/SH10146     Document Type: Article

References (102)

1. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al.Decline in the AIDS and death rates in the EuroSIDA study: An observational study.Lancet 2003; 362: 22-9.doi:10.1016/S0140-6736(03)13802-0 (Pubitemid 36835816)
2. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F.Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals.AIDS 2010; 24: 1527-35.doi:10.1097/QAD.0b013e32833a3946
3. Health Protection Agency.Survey of prevalent HIV infections diagnosed (SOPHID) data tables 2009.London: Health Protection Agency; 2010.Available online at: http://www.hpa.org.uk/web/ HPAwebFile/HPAweb-C/1221482342 683 [verified March 2011].
4. European AIDS Clinical Society (EACS).Guidelines: prevention and management of non-infectious co-morbidities in HIV.Paris: EACS.Available online at: http://www.europeanaidsclinicalsociety.org/guidelinespdf/2-Non-Infectious- Co-Morbidities-in-HIV.pdf[verified March 2011].
5. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P.Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.Crit Care 2004; 8: R204-12.doi:10.1186/ cc2872
6. Feest TG, Round A, Hamad S.Incidence of severe acute renal failure in adults: results of a community based study.BMJ 1993; 306: 481-3.doi:10.1136/bmj. 306.6876.481 (Pubitemid 23053155)
7. Leblanc M, Kellum JA, Gibney RT, Lieberthal W, Tumlin J, Mehta R.Risk factors for acute renal failure: inherent and modifiable risks.Curr Opin Crit Care 2005; 11: 533-6.doi:10.1097/01.ccx.0000183 666.54717.3d (Pubitemid 41697323)
8. Metcalfe W, Simpson M, Khan IH, Prescott GJ, Simpson K, Smith WC, et al.Acute renal failure requiring renal replacement therapy: incidence and outcome.QJM 2002; 95: 579-83.doi:10.1093/qjmed/ 95.9.579
9. Wyatt CM, Arons RR, Klotman PE, Klotman ME.Acute renal failure in hospitalized patients with HIV: risk factors and impact on inhospital mortality.AIDS 2006; 20: 561-5.doi:10.1097/01.aids.0000 210610.52836.07 (Pubitemid 43731600)
10. Franceschini N, Napravnik S, Eron JJ Jr, Szczech LA, Finn WF.Incidence and etiology of acute renal failure among ambulatory HIVinfected patients.Kidney Int 2005; 67: 1526-31.doi:10.1111/j.1523- 1755.2005.00232.x (Pubitemid 40463131)
11. Roe J, Campbell LJ, Ibrahim F, Hendry BM, Post FA.HIV care and the incidence of acute renal failure.Clin. Infect. Dis. 2008; 47: 242-9.doi:10.1086/589296 (Pubitemid 351920627)
12. Ibrahim F, Naftalin C, Cheserem E, Roe J, Campbell LJ, Bansi L, et al.Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure.AIDS 2010; 24: 2239-44.doi:10.1097/QAD.0b013e32833c85d6
13. Franceschini N, Napravnik S, Finn WF, Szczech LA, Eron JJ Jr.Immunosuppression, hepatitis C infection, and acute renal failure in HIV-infected patients.J. Acquir. Immune. Defic. Syndr. 2006; 42: 368-72.doi:10.1097/01.qai.0000220165.79736.d3 (Pubitemid 44050017)
14. Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, et al.Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey.BMJ 2006; 333: 1047.doi:10.1136/bmj. 39001.657755.BE (Pubitemid 44807817)
15. Brenner BM, Lazarus JM.Chronic renal failure.In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, editors.Harrison's principles of internal medicine.Thirteenth edn.New York: McGraw-Hill; 1994.
16. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al.Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative metaanalysis.Lancet 2010; 375: 2073-81.doi:10.1016/S0140-6736 (10)60674-5
17. Ansell D, Castledean C, Feehally J, Fogarty D, Ford D, Inward C, et al.The twelfth annual report December 2009.Bristol: UK Renal Registry; 2009.Available online at: http://www.renalreg.com/ Reports/2009.html [verified March 2011].
18. Excell L,McDonald S.2009Annual Report,Australia&New Zealand Dialysis and Transplant Registry, Chapter 1: Stock and flow.Available online at: http://www.anzdata.org.au/anzdata/Anzdata Report/32ndReport/Ch01.pdf [verified March 2011].
19. Post FA, Holt SG.Recent developments in HIV and the kidney.Curr Opin Infect Dis 2009; 22: 43-8.doi:10.1097/QCO.0b013e32 8320ffec
20. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM.Racial differences in end-stage renal disease rates in HIV infection versus diabetes.J Am Soc Nephrol 2007; 18: 2968-74.doi:10.1681/ASN.2007040402 (Pubitemid 350058405)
21. Bansi L, Hughes A, Bhagani S, Mackie NE, Leen C, Levy J, et al.Clinical epidemiology of HIV-associated end-stage renal failure in the UK.AIDS 2009; 23: 2517-21.doi:10.1097/QAD.0b013e3 283320e12
22. Post FA, Campbell LJ, Hamzah L, Collins L, Jones R, Siwani R, et al.Predictors of renal outcome in HIV-associated nephropathy.Clin. Infect. Dis. 2008; 46: 1282-9.doi:10.1086/529385 (Pubitemid 351589915)
23. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD.Highly active antiretroviral therapy and the incidence of HIV-1- associated nephropathy: A 12-year cohort study.AIDS 2004; 18: 541-6.doi:10.1097/00002030- 200402200-00022 (Pubitemid 38365883)
24. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, et al.The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection.Kidney Int 2004; 66: 1145-52.doi:10.1111/j.1523-1755.2004. 00865.x (Pubitemid 39121021)
25. Berliner AR, Fine DM, Lucas GM, Rahman MH, Racusen LC, Scheel PJ, et al.Observations on a cohort of HIV-infected patients undergoing native renal biopsy.Am J Nephrol 2008; 28: 478-86.doi:10.1159/000112851 (Pubitemid 351501614)
26. Herman ES, Klotman PE.HIV-associated nephropathy: epidemiology, pathogenesis, and treatment.Semin Nephrol 2003; 23: 200-8.doi:10.1053/snep.2003. 50018 (Pubitemid 36397102)
27. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, et al.MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.Nat Genet 2008; 40: 1175-84.doi:10.1038/ng.226
28. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, et al.Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.Hum Genet 2010; 128: 345-50.doi:10.1007/s00439-010- 0861-0
29. Atta MG, Gallant JE, Rahman MH, Nagajothi N, Racusen LC, Scheel PJ, et al.Antiretroviral therapy in the treatment of HIVassociated nephropathy.Nephrol Dial Transplant 2006; 21: 2809-13.doi:10.1093/ndt/gfl337 (Pubitemid 44542235)
30. Choi A, Rodriguez R, Bacchetti P, Volberding P, Havlir D, Bertenthal D, et al.Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease.Clin. Infect. Dis. 2007; 45: 1633-9.doi:10.1086/523729 (Pubitemid 351411850)
31. Gerntholtz TE, Goetsch SJ, Katz I.HIV-related nephropathy: A South African perspective.Kidney Int 2006; 69: 1885-91.doi:10.1038/ sj.ki.5000351 (Pubitemid 43739220)
32. Haas M, Kaul S, Eustace JA.HIV-associated immune complex glomerulonephritis with "lupus-like" features: A clinicopathologic study of 14 cases.Kidney Int 2005; 67: 1381-90.doi:10.1111/j.1523- 1755.2005.00215.x (Pubitemid 40463114)
33. Lucas GM, Mehta SH, Atta MG, Kirk GD, Galai N, Vlahov D, et al.End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004.AIDS 2007; 21: 2435-43.doi:10.1097/QAD.0b013e32827038ad (Pubitemid 350145175)
34. Atta MG, Fine DM, Kirk GD, Mehta SH, Moore RD, Lucas GM.Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland.Clin. Infect. Dis. 2007; 45: 1625-32.doi:10.1086/ 523728 (Pubitemid 351411849)
35. Bhagani S, Sweny P, Brook G.Guidelines for kidney transplantation in patients with HIV disease.HIV Med 2006; 7: 133-9.doi:10.1111/ j.1468-1293.2006.00367.x
36. Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, et al.HIV-infected liver and kidney transplant recipients: 1- and 3- year outcomes.Am J Transplant 2008; 8: 355-65.doi:10.1111/ j.1600-6143.2007.02061.x
37. Trullas JC, Mocroft A, Cofan F, Tourret J, Moreno A, Bagnis CI, et al.Dialysis and renal transplantation in HIV-infected patients: A European survey.J. Acquir. Immune. Defic. Syndr. 2010; 55: 582-9.doi:10.1097/QAI. 0b013e3181efbe59
38. Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, et al.Outcomes of kidney transplantation in HIV-infected recipients.N. Engl. J. Med. 2010; 363: 2004-14.doi:10.1056/NEJMoa1001197
39. Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, et al.Chronic renal failure among HIV-1-infected patients.AIDS 2007; 21: 1119-27.doi:10.1097/QAD.0b013e3280f774ee (Pubitemid 46763282)
40. Wyatt CM, Winston JA, Malvestutto CD, Fishbein DA, Barash I, Cohen AJ, et al.Chronic kidney disease in HIV infection: An urban epidemic.AIDS 2007; 21: 2101-3.doi:10.1097/QAD.0b013e32 82ef1bb4 (Pubitemid 47462160)
41. Cheung CY, Wong KM, Lee MP, Liu YL, Kwok H, Chung R, et al.Prevalence of chronic kidney disease in Chinese HIV-infected patients.Nephrol Dial Transplant 2007; 22: 3186-90.doi:10.1093/ndt/gfm350 (Pubitemid 350202545)
42. Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA.Spectrum of chronic kidney disease in HIV-infected patients.HIV Med 2009; 10: 329-36.doi:10.1111/j.1468-1293.2008.00691.x
43. Fernando SK, Finkelstein FO, Moore BA, Weissman S.Prevalence of chronic kidney disease in an urban HIV infected population.Am J Med Sci 2008; 335: 89-94.doi:10.1097/MAJ.0b013e31812e6b34 (Pubitemid 351253402)
44. Sorlí ML, Guelar A, Montero M, Gonzalez A, Rodriguez E, Knobel H.Chronic kidney disease prevalence and risk factors among HIVinfected patients.J. Acquir. Immune. Defic. Syndr. 2008; 48: 506-8.doi:10.1097/QAI. 0b013e31817bbecb
45. Odden MC, Scherzer R, Bacchetti P, Szczech LA, Sidney S, Grunfeld C, et al.Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: The FRAM study.Arch Intern Med 2007; 167: 2213-9.doi:10.1001/ archinte.167.20.2213 (Pubitemid 350106741)
46. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, et al.Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.AIDS 2010; 24: 1667-78.doi:10.1097/QAD.0b013e328339fe53
47. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al.Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection.J. Infect. Dis. 2010; 201: 1788-95.doi:10.1086/652749
48. Kalayjian RC, Franceschini N, Gupta SK, Szczech LA, Mupere E, Bosch RJ, et al.Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease.AIDS 2008; 22: 481-7.doi:10.1097/ QAD.0b013e3282f4706d (Pubitemid 351317289)
49. Reid A, Stohr W, Walker AS, Williams IG, Kityo C, Hughes P, et al.Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.Clin. Infect. Dis. 2008; 46: 1271-81.doi:10.1086/533468 (Pubitemid 351589914)
50. Choi AI, Shlipak MG, Hunt PW, Martin JN, Deeks SG.HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy.AIDS 2009; 23: 2143-9.doi:10.1097/ QAD.0b013e3283313c91
51. Wever K, van Agtmael MA, Carr A.Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men.J. Acquir. Immune. Defic. Syndr. 2010; 55: 78-81.doi:10.1097/QAI.0b013e31 81d05579
52. Campbell LJ, Hamzah L, Post FA.Is tenofovir-related renal toxicity incompletely reversible? J. Acquir. Immune. Defic. Syndr. 2011; 56: e95.doi:10.1097/QAI.0b013e318202f1b8
53. Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, Cohen MH, et al.Predictors of proteinuria and renal failure among women with HIV infection.Kidney Int 2002; 61: 195-202.oi:10.1046/j.1523-1755.2002.00094.x (Pubitemid 34075147)
54. Gardner LI, Holmberg SD, Williamson JM, Szczech LA, Carpenter AM, et al.Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women.J. Acquir. Immune. Defic. Syndr. 2003; 32: 203-9. (Pubitemid 36222723)
55. Szczech LA, Grunfeld C, Scherzer R, Canchola JA, van der Horst C, Sidney S, et al.Microalbuminuria in HIV infection.AIDS 2007; 21: 1003-9.doi:10.1097/ QAD.0b013e3280d3587f (Pubitemid 46684331)
56. Gupta SK, Smurzynski M, Franceschini N, Bosch RJ, Szczech LA, Kalayjian RC.The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era.Antivir Ther 2009; 14: 543-9.
57. Wyatt CM, Hoover DR, Shi Q, Seaberg E, Wei C, Tien PC, et al.Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection.J. Acquir. Immune. Defic. Syndr. 2010; 55: 73-7.
58. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG.Kidney function and the risk of cardiovascular events in HIV-1- infected patients.AIDS 2010; 24: 387-94.doi:10.1097/QAD.0b013e3283359253
59. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG.Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons.Circulation 2010; 121: 651-8.doi:10.1161/ CIRCULATIONAHA.109.898585
60. Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, et al.Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir.AIDS 2009; 23: 689-96.doi:10.1097/QAD.0b013e 3283262a64
61. Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, et al.Association between ABCC2 gene haplotypes and tenofovirinduced proximal tubulopathy.J. Infect. Dis. 2006; 194: 1481-91.doi:10.1086/508546 (Pubitemid 44851889)
62. Rodríguez-Nóvoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, et al.Predictors of kidney tubular dysfunction in HIVinfected patients treated with tenofovir: A pharmacogenetic study.Clin. Infect. Dis. 2009; 48: e108-16.doi:10.1086/598507
63. Rodríguez-Nóvoa S, Labarga P, D'Avolio A, Barreiro P, Albalate M, Vispo E, et al.Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.AIDS 2010; 24: 1064-6.doi:10.1097/QAD.0b013 e32833202e2
64. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, et al.Mechanism of active renal tubular efflux of tenofovir.Antimicrob Agents Chemother 2006; 50: 3297-304.doi:10.1128/AAC.00251-06 (Pubitemid 44527501)
65. Ray AS, Cihlar T.Unlikely association of multidrug-resistance protein 2 single-nucleotide polymorphisms with tenofovir-induced renal adverse events.J. Infect. Dis. 2007; 195: 1389-90, author reply 90-1.doi:10.1086/513282 (Pubitemid 46649628)
66. Fux C, Hasse B, Opravil M, Cavassini M, Calmy A, GurtnerdelaFuente V, et al.Bone turnover, and in particular osteoclast activity, is increased in patients with confirmed proximal renal tubulopathy within the Swiss HIV Cohort Study.17th Conference on Retroviruses and Opportunistic Infections; February 16-19 2010; CA, USA.
67. Hall AM, Edwards SG, Lapsley M, Connolly JO, Chetty K, O'Farrel S, et al.Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: A cross-sectional analysis.Am J Kidney Dis 2009; 54: 1034-42.doi:10.1053/j.ajkd.2009.07.012
68. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, et al.Tenofovir-associated renal and bone toxicity.HIV Med 2009; 10: 482-7.doi:10.1111/j.1468-1293.2009.00716.x
69. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G.Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions.Clin. Infect. Dis. 2006; 42: 283-90.doi:10.1086/499048 (Pubitemid 43054205)
70. Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW.The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy.HIV Med 2005; 6: 341-6.doi:10.1111/j.1468- 1293.2005.00318.x (Pubitemid 41335143)
71. Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, et al.Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.Clin. Infect. Dis. 2005; 40: 1559-85.doi:10.1086/ 430257 (Pubitemid 40720806)
72. Electronic Medicines Compendium.Tenofovir SPC.Summary of product characteristics: Viread 245 mg film-coated tablets.Surrey: Electronic Medicines Compendium; 2010.Available online at: http://www.medicines.org.uk/emc/medicine/ 9008 [verified March 2011].
73. Day SL, Leake Date HA, Bannister A, Hankins M, Fisher M.Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice.J. Acquir. Immune. Defic. Syndr. 2005; 38: 301-4. (Pubitemid 40333495)
74. Post FA, Wyatt CM, Mocroft A.Biomarkers of impaired renal function.Curr Opin HIV AIDS 2010; 5: 524-30.doi:10.1097/COH.0b013e32833f203e
75. Bagnis CI, Deray G.Renal consequences of HIV and HIV therapy.Curr Opin HIV AIDS 2007; 2: 314-7.doi:10.1097/COH.0b01 3e3281ca6fbe (Pubitemid 46941825)
76. Tourret J, Tostivint I, Tezenas Du Montcel S, Karie S, Launay- Vacher V, Vigneau C, et al.Antiretroviral drug dosing errors in HIVinfected patients undergoing hemodialysis.Clin. Infect. Dis. 2007; 45: 779-84.doi:10.1086/521168 (Pubitemid 47378893)
77. Electronic Medicines Compendium.Atazanavir SPC.Summary of product characteristics: Reyataz 150 mg, 200 mg and 300 mg hard capsules.Surrey: Electronic Medicines Compendium; 2010.Available online at: http://www.medicines. org.uk/emc/medicine/ 14145 [verified March 2011].
78. Davies DF, Shock NW.Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males.J Clin Invest 1950; 29: 496-507.doi:10.1172/JCI102286
79. Hoang K, Tan JC, Derby G, Blouch KL, Masek M, Ma I, et al.Determinants of glomerular hypofiltration in aging humans.Kidney Int 2003; 64: 1417-24.doi:10.1046/j.1523-1755.2003.00207.x (Pubitemid 37153808)
80. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY.Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.N. Engl. J. Med. 2004; 351: 1296-305.doi:10.1056/ NEJMoa041031
81. Keller G, Zimmer G, Mall G, Ritz E, Amann K.Nephron number in patients with primary hypertension.N. Engl. J. Med. 2003; 348: 101-8.doi:10.1056/ NEJMoa020549 (Pubitemid 36056716)
82. Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG.The aging kidney.Kidney Int 2008; 74: 710-20.doi:10.1038/ki.2008.319
83. Kaplan C, Pasternack B, Shah H, Gallo G.Age-related incidence of sclerotic glomeruli in human kidneys.Am J Pathol 1975; 80: 227-34.
84. Jung FF, Kennefick TM, Ingelfinger JR, Vora JP, Anderson S.Down-regulation of the intrarenal renin-angiotensin system in the aging rat.J Am Soc Nephrol 1995; 5: 1573-80.
85. Kaysen GA, Myers BD.The aging kidney.Clin. Geriatr. Med. 1985; 1: 207-22. (Pubitemid 16087124)
86. Weidmann P, De Myttenaere-Bursztein S, Maxwell MH, de Lima J.Effect on aging on plasma renin and aldosterone in normal man.Kidney Int 1975; 8: 325-33.doi:10.1038/ki.1975.120
87. Cirillo M, Ciacci C, De Santo NG.Age, renal tubular phosphate reabsorption, and serum phosphate levels in adults.N. Engl. J. Med. 2008; 359: 864-6.doi:10.1056/NEJMc0800696
88. Lindeman RD.Assessment of renal function in the old.Special considerations.Clin Lab Med 1993; 13: 269-77. (Pubitemid 23097086)
89. Mavigner M, Delobel P, Cazabat M, Dubois M, L'Faqihi-Olive FE, Raymond S, et al.HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.PLoS ONE 2009; 4: e7658.doi:10.1371/ journal.pone.0007658
90. Deeks SG, Phillips AN.HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity.BMJ 2009; 338: A3172.doi:10.1136/bmj.a3172
91. Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, et al.Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study.AIDS 2009; 23: 1841-9.doi:10.1097/ QAD.0b013e32832d3b85
92. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, et al.Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis.AIDS 2009; 23: 1059-67.doi:10.1097/QAD. 0b013e32832b514b
93. Kingsley LA, Cuervo-Rojas J, Munoz A, Palella FJ, Post W, Witt MD, et al.Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: multicenter AIDS Cohort Study.AIDS 2008; 22: 1589-99.doi:10.1097/QAD. 0b013e328306a6c5
94. Fitch KV, Lo J, Abbara S, Ghoshhajra B, Shturman L, Soni A, et al.Increased coronary artery calcium score and noncalcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters.J. Acquir. Immune. Defic. Syndr. 2010; 55: 495-9.doi:10.1097/QAI. 0b013e3181edab0b
95. Baker JV, Duprez D, Rapkin J, Hullsiek KH, Quick H, Grimm R, et al.Untreated HIV infection and large and small artery elasticity.J. Acquir. Immune. Defic. Syndr. 2009; 52: 25-31.doi:10.1097/QAI.0b013e3181b02e6a
96. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al.Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.PLoS Med 2008; 5: e203.doi:10.1371/ journal.pmed.0050203
97. Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, et al.Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ ritonavir for initial HIV treatment.AIDS 2009; 23: 1547-56.doi:10.1097/QAD.0b013e32832cbcc2
98. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al.CD4+ count-guided interruption of antiretroviral treatment.N. Engl. J. Med. 2006; 355: 2283-96.doi:10.1056/NEJMoa062360 (Pubitemid 44837777)
99. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al.Class of antiretroviral drugs and the risk of myocardial infarction.N. Engl. J. Med. 2007; 356: 1723-35.doi:10.1056/NEJ Moa062744 (Pubitemid 46658704)
100. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al.Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A:D study: A multi-cohort collaboration.Lancet 2008; 371: 1417-26.doi:10.1016/S0140-6736(08)60423-7
101. Brown TT, Qaqish RB.Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review.AIDS 2006; 20: 2165-74.doi:10.1097/QAD.0b013e32801022eb (Pubitemid 44684707)
102. Triant VA, Brown TT, Lee H, Grinspoon SK.Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non- HIV-infected patients in a large U.S.healthcare system.J Clin Endocrinol Metab 2008; 93: 3499-504.doi:10.1210/jc.2008-0828 492 Sexual Health C.Naftalin et al.www.publish.